Press Releases
Jun 27, 2022

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do not respond to existing cancer...

Jun 26, 2022

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the US Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2...

Jun 23, 2022

Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...

EXPLORE ALL US PRESS RELEASES

Articles
Jun 14, 2022

Great Place to Work and Fortune magazine have honored Astellas as one of this year’s Best Workplaces in Chicago. Astellas, ranked #X, is among the best companies to work for headquartered in...

Jun 10, 2022

As part of our commitment to Engagement, Diversity, and Inclusion, and the wellbeing of our employees, Astellas offers a comprehensive parental benefits package, assisting Astellas families in...

Apr 28, 2022

Astellas is proud to share recent top leadership promotions and appointments across our divisions for employees based in the US. These leaders are all crucial in driving forward the company’s...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products